Dr. Reddy's Laboratories Limited vs Galapagos NV: Annual Revenue Growth Compared

Biopharma Revenue Race: Dr. Reddy's vs. Galapagos

__timestampDr. Reddy's Laboratories LimitedGalapagos NV
Wednesday, January 1, 201413217000000069368000
Thursday, January 1, 201514818900000039563000
Friday, January 1, 2016154708000000129517000
Sunday, January 1, 2017140809000000127087000
Monday, January 1, 2018142028000000288836000
Tuesday, January 1, 2019153851000000844986000
Wednesday, January 1, 2020174600000000478053000
Friday, January 1, 2021189722000000484846000
Saturday, January 1, 2022214391000000505280000
Sunday, January 1, 2023245879000000239724000
Monday, January 1, 2024279164000000
Loading chart...

Unleashing insights

A Tale of Two Biopharma Giants: Revenue Growth from 2014 to 2023

In the dynamic world of biopharmaceuticals, Dr. Reddy's Laboratories Limited and Galapagos NV have charted distinct paths over the past decade. Dr. Reddy's, a stalwart in the industry, has seen its revenue grow by approximately 111% from 2014 to 2023, reflecting its robust market strategies and expanding global footprint. In contrast, Galapagos NV, a smaller yet innovative player, experienced a more volatile revenue trajectory, peaking in 2019 before facing fluctuations. By 2023, Dr. Reddy's revenue was nearly 1,000 times that of Galapagos, underscoring the scale difference between the two. However, Galapagos' focus on niche markets and cutting-edge research continues to position it as a formidable contender. As we look to the future, the absence of 2024 data for Galapagos leaves room for speculation on its next strategic move.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025